Trial reportEuropean journal of nuclear medicine and molecular imaging2023
Longitudinal head-to-head comparison of
Trial report in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01760005 (A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease.Acta neuropathologica · 2025Trial
- Development and Implementation of a Radiation Safety Screening Protocol for a Clinical Study Using Amyloid Positron Emission Tomography Imaging.Ochsner journal · 2026Article
- Cerebral Amyloid Deposition WithHuman brain mapping · 2025Article
- A Robust Residual Three-dimensional Convolutional Neural Networks Model for Prediction of Amyloid-β Positivity by Using FDG-PET.Clinical nuclear medicine · 2025Article
- The striatum is an early, accurate indicator of amyloid burden using [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Accuracy and Longitudinal Consistency of PET/MR Attenuation Correction in Amyloid PET Imaging amid Software and Hardware Upgrades.AJNR. American journal of neuroradiology · 2025Article
- Comparison of accumulation rates of beta-amyloid tracers and their relationship with cognitive changes.Scientific reports · 2025Article
- Trends in Research on Gantenerumab for Alzheimer's Disease: A Bibliometric and Thematic Analysis.CNS & neurological disorders drug targets · 2025Article
- Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Evaluation of ComBat Harmonization for Reducing Across-Tracer Differences in Regional Amyloid PET Analyses.Human brain mapping · 2024Article
- The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core: An update.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Screening of [ACS pharmacology & translational science · 2024Article
- Two decades of [American journal of nuclear medicine and molecular imaging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors at 20 institutions in 7 countries.
Funding
Abstract
purposePittsburgh Compound-B (
methodsSixty-six mutation-positive participants enrolled in the gantenerumab and placebo arms of the first Dominantly Inherited Alzheimer Network Trials Unit clinical trial (DIAN-TU-001) underwent both
resultsIn the placebo arm, the absolute rate of longitudinal change measured by global cortical
conclusionGantenerumab treatment induces longitudinal changes in Aβ PET, and the absolute rates of these longitudinal changes differ significantly between Aβ radiotracers. These differences were not seen in the placebo arm, suggesting that Aβ-clearing treatments may pose unique challenges when attempting to compare longitudinal results across different Aβ radiotracers. Our results suggest converting Aβ PET SUVR measurements to Centiloids (both globally and regionally) can harmonize these differences without losing sensitivity to drug effects. Nonetheless, until consensus is achieved on how to harmonize drug effects across radiotracers, and since using multiple radiotracers in the same trial may increase type I error, multisite studies should consider potential variability due to different radiotracers when interpreting Aβ PET biomarker data and, if feasible, use a single radiotracer for the best results.
trial registrationClinicalTrials.gov NCT01760005. Registered 31 December 2012. Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.